APG Asset Management US Inc. Reduces Holdings in IQVIA Holdings Inc. (NYSE:IQV)

APG Asset Management US Inc. reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 51.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,767 shares of the medical research company's stock after selling 3,981 shares during the quarter. APG Asset Management US Inc.'s holdings in IQVIA were worth $740,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in IQV. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the 4th quarter worth approximately $33,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. grew its holdings in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc raised its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after buying an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in shares of IQVIA during the 4th quarter worth approximately $60,000. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 1.6 %

Shares of IQVIA stock traded down $2.36 during trading hours on Tuesday, reaching $148.56. The company's stock had a trading volume of 332,208 shares, compared to its average volume of 1,384,415. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a market capitalization of $26.19 billion, a P/E ratio of 19.81, a P/E/G ratio of 1.99 and a beta of 1.46. The stock's fifty day simple moving average is $181.23 and its two-hundred day simple moving average is $198.80.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

IQV has been the subject of several research reports. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Robert W. Baird lowered their price objective on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Finally, Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 price objective for the company. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.